Infection with human T-lymphotropic virus types-and -(HTLV-and -2): Implications for blood transfusion safety

Transfusion Clinique et Biologique

Volumn 23, Issue 1, 2016, Pages 13-19

  Murphy, E L ^a  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

Author keywords

Blood transfusion; HTLV 1; Immunoassay; Prevention and control

Indexed keywords

HUMAN T CELL LEUKEMIA VIRUS ANTIBODY;

ANTIBODY SCREENING; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; COST EFFECTIVENESS ANALYSIS; HIGH INCOME COUNTRY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS INFECTION; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; INCIDENCE; INFECTION PREVENTION; LEUKAPHERESIS; LYMPHOCYTE; NONHUMAN; PREVALENCE; RISK ASSESSMENT; SAFETY; SOCIOECONOMICS; VIRUS TRANSMISSION; ADVERSE EFFECTS; BLOOD; BLOOD SAFETY; COST BENEFIT ANALYSIS; DONOR SELECTION; ECONOMICS; FORECASTING; HEALTH; HTLV-I INFECTIONS; HTLV-II INFECTIONS; ISOLATION AND PURIFICATION; SEROCONVERSION; STANDARDS; TRANSMISSION; VIREMIA; VIROLOGY;

BLOOD DONORS; BLOOD SAFETY; BLOOD TRANSFUSION; COST-BENEFIT ANALYSIS; DONOR SELECTION; FORECASTING; GLOBAL HEALTH; HTLV-I INFECTIONS; HTLV-II INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; HUMANS; LEUKOCYTE REDUCTION PROCEDURES; LYMPHOCYTES; PREVALENCE; SEROCONVERSION; VIREMIA;

EID: 84958162214     PISSN: 12467820     EISSN: 19538022     Source Type: Journal    
DOI: 10.1016/j.tracli.2015.12.001     Document Type: Article

References (46)

1. Massari V., et al. Epidemiologic comparison of human T-lymphotropic virus type I-infected blood donors from endemic and nonendemic regions over a 3-year period. Transfusion 1994, 34:198-201.
2. Lefrere J.J. Human T-lymphotropic virus type I (HTLV-I): risk of transmission with transfusion. Presse Med 2000, 29:1134-1138.
3. Okochi K., Sato H., Hinuma Y. A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: seroconversion in recipients. Vox Sang 1984, 46:245-253.
4. Manns A., et al. A prospective study of transmission by transfusion of HTLV-and risk factors associated with seroconversion. Int J Cancer 1992, 51:886-891.
5. Donegan E., et al. Transfusion of blood components from a donor with human T-lymphotropic virus type II (HTLV-II) infection. The Transfusion Safety Study Group. Ann Intern Med 1990, 113:555-556.
6. Kleinman S., et al. Transfusion transmission of human T-lymphotropic virus types I and II: serologic and polymerase chain reaction results in recipients identified through look-back investigations. Transfusion 1993, 33:14-18.
7. O'Brien S.F., et al. The epidemiology of human T-cell lymphotropic virus types I and II in Canadian blood donors. Transfus Med 2013, 23:358-366.
8. Gout O., et al. Rapid development of myelopathy after HTLV-infection acquired by transfusion during cardiac transplantation. N Engl J Med 1990, 322:383-388.
9. Chen Y.C., et al. Infection of human T-cell leukemia virus type I and development of human T-cell leukemia lymphoma in patients with hematologic neoplasms: a possible linkage to blood transfusion. Blood 1989, 74:388-394.
10. Hakre S., et al. Transfusion-transmitted human T-lymphotropic virus Type I infection in a United States military emergency whole blood transfusion recipient in Afghanistan, 2010. Transfusion 2013, 53:2176-2182.
11. Gessain A., Cassar O. Epidemiological Aspects and World Distribution of HTLV-Infection. Front Microbiol 2012, 3:p388.
12. Mueller N., et al. Epidemiologic perspectives of HTLV-I, in human retrovirology: HTLV 1990, 281-294. Lippincott-Raven, Philadelphia. W.A. Blattner (Ed.).
13. Satake M., Yamaguchi K., Tadokoro K. Current prevalence of HTLV-in Japan as determined by screening of blood donors. J Med Virol 2012, 84:327-335.
14. Du J., et al. History and update of HTLV infection in China. Virus Res 2014, 191:134-137.
15. Vidal A.U., et al. Phylogenetic classification of human T cell leukaemia/lymphoma virus type I genotypes in five major molecular and geographical subtypes. J Gen Virol 1994, 75:3655-3666.
16. Blattner W.A., et al. A study of HTlV-and its associated risk factors in Trinidad and Tobago. J Acq Immun Def Synd 1990, 3:1102-1108.
17. Maloney E.M., et al. Human T-lymphotropic virus type I (HTLV-I) seroprevalence in Jamaica: II. Geographic and ecologic determinants. Am J Epid 1991, 133:1125-1134.
18. Murphy E.L., et al. Sexual transmission of human T-lymphotropic virus type I (HTLV-I). Ann Intern Med 1989, 111:555-560.
19. Carneiro-Proietti A.B., et al. HTLV-and -seroprevalence, incidence and residual transfusion risk among blood donors in Brazil during 2007-2009. AIDS Res Hum Retroviruses 2012.
20. Carneiro-Proietti A.B., et al. HTLV in the Americas: challenges and perspectives. Rev Panam Salud Publica 2006, 19:44-53.
21. Chang Y.B., et al. Seroprevalence and demographic determinants of human T-lymphotropic virus type 1 and 2 infections among first-time blood donors-United States, 2000-2009. J Infect Dis 2014, 209:523-531.
22. Lee H.H., et al. Relative prevalence and risk factors of HTLV-and HTLV-II infection in US blood donors. Lancet 1991, 337:1435-1439.
23. Roberts C.R., et al. Prevalence of human T-lymphotropic virus in civilian applicants for the United States armed forces. Amer J Public Health 1992, 82:70-73.
24. Blattner W.A., et al. Modes of transmission and evidence for viral latency from studies of human T-cell lymphotrophic virus type I in Japanese migrant populations in Hawaii. Proc Natl Acad Sci U S A 1986, 83:4895-4898.
25. Ho G., et al. Declining HTLV-seroprevalence in Japanese immigrant population in Hawaii. Am J Epid 1991, 134:981-987.
26. Mahieux R., et al. Human T-cell lymphotropic virus type 1 gag indeterminate western blot patterns in Central Africa: relationship to Plasmodium falciparum infection. J Clin Microbiol 2000, 38(11):4049-4057.
27. Delaporte E., et al. Seroepidemiological survey of HTLV-infection among randomized populations of western central African countries. J Acquir Immune Defic Syndr 1989, 2:410-413.
28. Sykes W., et al. Prevalence of HTLV-in the South African Donor Population 2013. (Abstract P318). Vox Sang 2014, 107:160.
29. Farid R., et al. Seroepidemiology and virology of HTLV-in the city of Mashhad, northeastern Iran. Serodiagn Immunother Infect Dis 1993, 5:p251.
30. Maghsudlu M., Safabakhsh H., Jamili P. Seroepidemiology of human T-cell lymphotropic virus type-in blood donors of Northeastern Iran, Sabzevar. Asian J Transfus Sci 2015, 9(2):203-206.
31. Price J., et al. Human T-cell leukaemia/lymphoma virus risk may be enhanced in some selected donor populations. Vox Sang 2001, 80:148-150.
32. Laperche S., Worms B., Pillonel J. Blood safety strategies for human T-cell lymphotropic virus in Europe. Vox Sang 2009, 96:104-110.
33. Reeves W.C., et al. Human T cell lymphotropic virus infection in Guaymi Indians from Panama. Am J Trop Med Hyg 1990, 43:410-418.
34. Biggar R.J., et al. Antibody to human retroviruses among drug users in three east coast American cities, 1972-1976. J Infect Dis 1991, 163:57-63.
35. Khabbaz R.F., et al. Seroprevalence of HTLV-and HTLV-among intravenous drug users and persons in clinics for sexually transmitted diseases. N Engl J Med 1992, 326:375-380.
36. Schreiber G.B., et al. Risk factors for human T-cell lymphotropic virus types I and II (HTLV-and -II) in blood donors: the Retrovirus Epidemiology Donor Study. NHLBI Retrovirus Epidemiology Donor Study. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:263-271.
37. Schreiber G.B., et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996, 334:1685-1690.
38. Glynn S.A., et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS). JAMA 2000, 284:229-235.
39. Zou S., Stramer S.L., Dodd R.Y. Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations. Transfus Med Rev 2012, 26:119-128.
40. Laperche S., Pillonel J. Relevance of safety measures to avoid HTLV transmission by transfusion in 2014. Transfus Clin Biol 2014, 21:167-172.
41. Marano G., et al. Human T-lymphotropic virus and transfusion safety: does one size fit all?. Transfusion 2015.
42. Courouce A.M., et al. HTLV testing in blood transfusion. Vox Sang 1998, 74:165-169.
43. Stigum H., et al. Human T-cell lymphotropic virus testing of blood donors in Norway: a cost-effect model. Int J Epidemiol 2000, 29:1076-1084.
44. Seed C.R., Kiely P., Keller A.J. Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus. Intern Med J 2005, 35:592-598.
45. Hewitt P.E., et al. Human T-lymphotropic virus lookback in NHS Blood and Transplant (England) reveals the efficacy of leukoreduction. Transfusion 2013, 53:2168-2175.
46. Sobata R., et al. Estimation of the infectious viral load required for transfusion-transmitted human T-lymphotropic virus type 1 infection (TT-HTLV-1) and of the effectiveness of leukocyte reduction in preventing TT-HTLV-1. Vox Sang 2015, 109:122-128.